Efficacy and safety of sofosbuvir-based direct antiviral therapy for chronic hepatitis C in children
10.3760/cma.j.cn112866-20201109-00281
- VernacularTitle:索磷布韦为基础的直接抗病毒药物治疗儿童慢性丙型肝炎的疗效及安全性
- Author:
Limin WANG
1
;
Meiying HUANG
;
Yi DONG
;
Min ZHANG
;
Zhiqiang XU
;
Fuchuan WANG
;
Shishu ZHU
Author Information
1. 解放军总医院第五医学中心 青少年肝病中心，北京 100039
- Keywords:
Hepatitis C;
Chronic;
Children;
Treatment;
Sofosbuvir
- From:
Chinese Journal of Experimental and Clinical Virology
2022;36(2):195-198
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of direct antiviral drugs based on sofosbuvir in the treatment of chronic hepatitis C in children.Methods:Data of children diagnosed with chronic hepatitis C from May 2017 to December 2019 and received sofosbuvir (SOF, body weight ≥ 17 kg 200 mg/d, <17 kg 150 mg/d)/ledipasvir (LDV, body mass ≥ 17 kg 45 mg/d, <17 kg 33.75 mg/d) or velpatasvir (VEL, body weight ≥ 17 kg 50 mg/d), were collected. The patients were treated with ribavirin (RBV, 15 mg/kg·d) for 12 weeks and followed up for 12 weeks. The main outcome measures were sustained virological response (SVR) at 12 weeks follow-up after drug discontinuation, and the occurrence of adverse events during the treatment period was observed to evaluate the safety of the drug.Results:HCV RNA turned negative in 10 of the 13 children (76.92%), within 2 weeks after antiviral treatment, in 2 cases (15.38%) HCV RNA turned negative in 2-4 weeks, in 1 case (7.69%) RBV was added when HCV RNA did not turn negative in 8 weeks, but turned negative at 10 weeks. At 12 and 24 weeks after discontinuation of antiviral drugs (SVR12), HCV RNA continued to be negative, and at 24 weeks (SVR24), it was also negative. Adverse reactions: headache occurred in 2 cases (15.38%), fatigue in 3 cases (23.08%), no serious adverse reactions occurred in any of the patients.Conclusions:The efficacy and safety of direct antiviral drugs based on SOF in the treatment of children with chronic hepatitis C were good.
